Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates for ...
23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care. 23andMe, the genetic health and biopharmaceutical company, has partnered with ...
SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback